Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. (Nasdaq: CSTL) is a diagnostics company focused on molecular tests that guide patient care in dermatologic and gastroenterological disease. The CSTL news feed highlights company announcements, clinical data, financial results and corporate updates that shape how investors and clinicians view its role in precision medicine.
Readers can follow news on Castle’s core test portfolio, including DecisionDx-Melanoma for cutaneous melanoma, TissueCypher Barrett’s Esophagus, DecisionDx-SCC for high-risk cutaneous squamous cell carcinoma, MyPath Melanoma and its suite of tests for uveal melanoma such as DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq. Coverage also includes updates on AdvanceAD-Tx, the company’s gene expression profile test designed to guide systemic treatment decisions in moderate-to-severe atopic dermatitis.
In addition to product and clinical evidence updates, CSTL news items feature quarterly and annual financial results, test volume trends for core revenue drivers, and guidance ranges reported in earnings releases. Regulatory and corporate governance developments, such as bylaw amendments disclosed in Form 8-K filings, as well as participation in healthcare and investor conferences, are also common topics.
Because Castle Biosciences emphasizes rigorous clinical validation, many news releases center on new studies, meta-analyses and expert consensus papers that evaluate the performance of its tests in real-world and prospective cohorts. These articles provide insight into how DecisionDx-Melanoma, TissueCypher and other assays are being integrated into clinical decision-making.
For investors, clinicians and researchers tracking CSTL, this news page offers a centralized view of earnings announcements, product launches, reimbursement developments, clinical data presentations and corporate events related to Castle Biosciences’ molecular diagnostics business.
Castle Biosciences, Inc. (Nasdaq: CSTL) reported a 74% increase in Q1 2024 revenue over Q1 2023, reaching $73 million. Full-year revenue guidance for 2024 was raised to $255-265 million. The company delivered strong financial and operational results, showcasing growth in various test reports. Castle Biosciences continues to develop evidence supporting the clinical utility of its tests, with recent studies demonstrating potential healthcare savings and improved patient outcomes. The company's positive momentum in Q1 sets a solid foundation for continued success throughout the year.
Castle Biosciences, Inc. (Nasdaq: CSTL) kicks off Skin Cancer Awareness Month by supporting various initiatives. The company collaborates with IMPACT Melanoma to honor the City of Friendswood's designation as a Sun Safe Leadership Model City. The Sun Safe Leadership initiative includes programs like free sunscreen dispensers, portable shade tents, prevention education, and protective clothing for outdoor workers. Castle Biosciences partners with various organizations to raise awareness, support fundraising events, and provide education during Skin Cancer Awareness Month.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Castle Biosciences (CSTL)?
What is the market cap of Castle Biosciences (CSTL)?
